SkinVive by JUVÉDERM
First FDA-approved HA microdroplet for cheek skin quality improvement
이 치료에 대해
SkinVive by JUVÉDERM (Allergan) is the first FDA-approved HA microdroplet specifically for skin quality improvement. Unlike volumizing fillers, SkinVive distributes micro-droplets of HA throughout the dermis to fundamentally enhance skin hydration.
VYCAA HA technology (Vycross™ derivative) crosslinks low and high molecular weight HA at optimal ratio, creating micro-reservoirs that attract water molecules for natural radiance.
작용 기전
VYCAA-crosslinked modified HA distributes as micro-droplets throughout dermis. Each droplet acts as micro-reservoir attracting up to 1000x its weight in water. Sustained dermal hydration improves smoothness, moisture, and glow for 6+ months with minimal volumizing effect.
적응증
기대 효과
Single treatment provides 6+ months of skin quality improvement. Clinical trials show significant cheek smoothness score improvement. 90%+ patients report improved hydration and glow. Minimal volume change for natural results.
임상 근거
위험 및 부작용
Small bumps, redness, bruising at injection sites (resolves 1-3 days). Rare asymmetry. Very rare allergic reaction. Limited evidence for off-label use beyond cheeks.